Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $0.57 USD
Change Today -0.009 / -1.55%
Volume 4.8K
As of 8:10 PM 08/3/15 All times are local (Market data is delayed by at least 15 minutes).

nephros inc (NEPH) Snapshot

Previous Close
Day High
Day Low
52 Week High
08/27/14 - $1.15
52 Week Low
04/13/15 - $0.49
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for NEPHROS INC (NEPH)

Related News

No related news articles were found.

nephros inc (NEPH) Related Businessweek News

No Related Businessweek News Found

nephros inc (NEPH) Details

Nephros, Inc., a commercial stage medical device company, develops and sells high performance liquid purification filters primarily in the United States. It offers ultrafilters for hospitals and other commercial facilities that filter water for patient washing and drinking, as well as wound cleansing, medical equipment cleaning, and surgeons’ hands washing. The company also provides ultrafilters for dialysis centers that filters water or bicarbonate concentrate for use in hemodialysis devices, as well as clearance of toxins from blood in the treatment of patients with chronic renal failure; for individual water purification devices to produce drinking water for soldiers and backpackers in the military and outdoor recreation field; and for commercial facilities that filter water for use in ice machines and soda fountains. In addition, it offers products in the hemodiafiltration (HDF) modality to deliver therapy for end stage renal disease patients, which include OLpur mid-dilution HDF filter for HDF therapy; and OLpur H2H HDF module, an add-on module designed to allow the common types of hemodialysis machines for use in HDF therapy. The company was founded in 1997 and is headquartered in River Edge, New Jersey.

7 Employees
Last Reported Date: 06/23/15
Founded in 1997

nephros inc (NEPH) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

nephros inc (NEPH) Key Developments

Nephros, Inc. Receives Warning Letter from U.S. Food and Drug Administration

On May 28, 2015, Nephros, Inc. received a warning letter dated May 27, 2015 from the U.S. Food and Drug Administration resulting from an inspection of the company's facility in River Edge, New Jersey by the FDA's New Jersey District Office that occurred during October 2014. The Warning Letter alleges deficiencies relating to the company's compliance with the Quality System regulation and the Medical Device Reporting regulation. The company takes the matters identified in the Warning Letter seriously and is in the process of evaluating the corrective actions required to address the matters raised in the Warning Letter. The company also is in the process of preparing a response to the Warning Letter and intends to respond fully to the issues raised by the FDA within 15 business days as requested by the FDA, and to work diligently and expeditiously to resolve the issues raised by the FDA. The Warning Letter does not restrict the manufacture, production or shipment of any of the company's products, nor require the withdrawal of any product from the marketplace. However, failure to promptly address the issues raised in the Warning Letter to the FDA's satisfaction or to comply with U.S. medical device regulatory requirements in general could result in regulatory action being initiated by the FDA. These actions could include, among other things, delays in approval of any FDA applications, product seizures, injunctions and civil monetary penalties.

Nephros, Inc. Announces Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015

Nephros, Inc. announced unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported total net revenues were $544,000 compared to approximately $473,000 for the three months ended March 31, 2014. Loss from operations was $806,000 against $562,000 for the same period a year ago. Net profit was $243,000 compared to net loss of $3,511,000 for the same period a year ago. Net loss per diluted share was $0.02 against $0.19 for the same period a year ago.

Nephros, Inc. Appoints Malcolm Persen to its Board of Directors and as the Chair of the Audit Committee

Nephros, Inc. announced the appointment of Malcolm Persen, to its Board of Directors and as the Chair of the Audit Committee. Mr. Persen is currently the President of Resolute Performance Contracting, a solar construction firm that he founded in 2011. Previously, from 2009 through 2011, he was the Executive Vice President at Ironco Enterprises, a renewable energy contracting organization.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NEPH:US $0.57 USD -0.009

NEPH Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Baxter International Inc $39.51 USD -0.57
Fresenius Medical Care AG & Co KGaA €76.27 EUR -0.161
Nikkiso Co Ltd ¥1,040 JPY -138.00
View Industry Companies

Industry Analysis


Industry Average

Valuation NEPH Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 9.6x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 10.1x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NEPHROS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at